First Japanese Study of Electron IORT for Breast Cancer Yields No Recurrence at Five Years
SUNNYVALE, CA (PRWEB) September 22, 2015 -- In the first study of its kind in Japan, an industry leading journal, Radiation Oncology, has reported the results of a 5-year study reviewing electron based IORT as a method of accelerated partial breast irradiation (APBI) in Asian countries. The study, which cites utilizing the Mobetron® from IntraOp Medical Corporation, http://www.intraop.com, followed 32 enrollees from 2007 to 2010 and reports, “No recurrence or metastasis was observed in any patient.”
The Japanese study was conducted by Kawamura, et al. of Nagoya University and the Aichi Cancer Medical Hospital following 32 enrollees over a 3-year period with patients having a median age of 65 years old (51-81 range) with a median follow up time of 6 years. In the study, patients were given a single radiation treatment of 19-21 Gy with the Mobetron during the time of surgery with no recurring visits for radiotherapy. According to the findings, “No recurrence or metastasis was observed in any patient.” Other benefits of the technique noted by the authors were “avoiding unnecessary irradiation to the heart, lungs, and skin.”
IntraOp is the developer and manufacturer of the Mobetron, an intraoperative radiation device that uses low energy electrons to provide specialized treatment to cancer patients during the time of surgery, including women with breast cancer. The Mobetron has consistently demonstrated significant advantages in many studies and is contributing to changing the treatment protocols of breast and other incidents of cancer worldwide.
“We are pleased to see the results of the Kawamura study confirming what many of our users around the world have been reporting for years,” said IntraOp CEO Bruce Khouri. “In study after study, electron IORT using the Mobetron has demonstrated strong and consistent results for patients. And while the Kawamura study is relatively small, the fact that it is consistent with the positive data coming from many of our users in the US and Europe is a fact which the world cannot afford to ignore,” added Khouri.
Across the globe, users of the Mobetron are producing better or equivalent patient outcomes in less time, reducing or eliminating altogether the need for multiple radiation treatments while providing superior cosmetic results. The Mobetron allows doctors to deliver a single dose of electron based radiation to patients during their cancer surgery. For qualified patients the Mobetron delivers in a single, two-minute electron treatment the equivalent of six weeks of post-operative radiation therapy with x-rays.
“Important studies like the Kawamura study clearly demonstrate that electron IORT using the Mobetron delivers optimal cancer treatment to qualified patients by improving clinical outcomes, significantly lessening treatment times, reducing radiation exposure, and lowering overall costs," said Derek T. DeScioli, IntraOp’s VP of Global Sales. “As more and more of our users publish their long term data, the case for the Mobetron as the most effective and efficient APBI technique grows stronger,” added DeScioli.
About IntraOp Medical Corporation
IntraOp™ is a leading innovator of electron radiation devices for treating cancer as an adjunct to invasive surgical procedures. As the developer and manufacturer of Mobetron®, IntraOp pioneered the world’s first portable, self-shielded LINAC used for Intraoperative Radiation Therapy (IORT). Mobetron IORT is capable of delivering a precise dose of cancer killing electrons to any clinical target during surgery, when healthy tissue is not involved and cancer cells are most vulnerable. Based in Sunnyvale, California, IntraOp is a cancer care company helping unite radiation and surgical oncologists in the fight against cancer. For more information please visit http://www.intraop.com.
###
Product photography available upon request
Shepard Doniger, [email protected], http://www.smartteksystems.com, +1 (561) 637-5750, [email protected]
Share this article